Double-stranded oligonucleotides

Patent metadata

Field	Value
Publication number	US-9592250-B2
Application number	US-201414446022-A
Country	US
Kind code	B2
Filing date	Jul 29, 2014
Priority date	Feb 1, 2002
Publication date	Mar 14, 2017
Grant date	Mar 14, 2017

Abstract

Antisense sequences, including duplex RNAi compositions, which possess improved properties over those taught in the prior art are disclosed. The invention provides optimized antisense oligomer compositions and method for making and using the both in in vitro systems and therapeutically. The invention also provides methods of making and using the improved antisense oligomer compositions.

First claim

The invention claimed is:

1. A composition comprising a double-stranded oligonucleotide molecule, the molecule comprising:
a first strand and a second strand each having a length of less than 25 nucleotides and having a duplex length of at least 10 to at least 24 nucleotides;
wherein at least one of the first strand and the second strand contains a 5′-terminal phosphorous containing moiety;
wherein at least one but not all of the nucleotides of the first strand comprises a 2′-O-methyl modification and at least one but not all of the nucleotides of the second strand comprises a 2′-O-methyl modification, and
wherein said double-stranded oligonucleotide molecule is chemically synthesized.

2. The composition of claim 1 , wherein a strand of said double-stranded oligonucleotide molecule is complementary to a sequence of a target nucleic acid.

3. The composition of claim 2 wherein the target nucleic acid is a mRNA or a gene.

4. The composition of claim 2 wherein the target nucleic acid is present within a cell.

5. The composition of claim 4 wherein the cell is a eukaryotic cell.

6. The composition of claim 1 wherein the phosphorus containing moiety is selected from phosphate, phosphorothioate, or P-ethoxyphosphate.

7. The composition of claim 1 wherein the double-stranded oligonucleotide molecule is a double-stranded ribonucleic acid molecule.

8. A method for introducing a double-stranded ribonucleic acid molecule comprising a first strand and a second strand into a eukaryotic cell in vitro, the method comprising contacting the eukaryotic cell with the double-stranded ribonucleic acid molecule,
wherein the first strand and the second strand each have a length of less than 25 nucleotides and have a duplex length of at least 10 to at least 24 nucleotides,
wherein at least one but not all of the nucleotides of the first strand of the double-stranded ribonucleic acid molecule comprises a 2′-O-methyl modification;
wherein at least one but not all of the nucleotides of the second strand of the double-stranded ribonucleic acid molecule comprises a 2′-O-methyl modification;
wherein at least one of the first strand and the second strand contains a 5′-terminal phosphorus containing moiety; and
wherein said double-stranded ribonucleic acid molecule is chemically synthesized; to result in the double-stranded nucleic acid molecule being introduced into the eukaryotic cell.

9. The method of claim 8 , wherein the eukaryotic cell is contacted with the double-stranded ribonucleic acid molecule in the presence of a transfection agent.

10. The method of claim 9 , wherein the transfection reagent is a cationic lipid.

11. The method of claim 8 , wherein the double-stranded ribonucleic acid molecule is introduced into the cell by electroporation.

12. The method of claim 8 , wherein a strand of said double-stranded ribonucleic acid molecule is complementary to a sequence of an mRNA expressed in said eukaryotic cell.

13. The method of claim 8 , wherein a strand of the double-stranded ribonucleic acid molecule has at least 80% sequence complementarity with an mRNA expressed in the eukaryotic cell.

14. The method of claim 8 , wherein a strand of the double-stranded ribonucleic acid molecule has at least 90% sequence complementarity with an mRNA expressed in the eukaryotic cell.

15. The method of claim 8 , wherein a strand of the double-stranded ribonucleic acid molecule has at least 95% sequence complementarity with an mRNA expressed in the eukaryotic cell.

16. The method of claim 8 wherein the phosphorus containing moiety is selected from phosphate, phosphorothioate, or P-ethoxyphosphate.

Assignees

• Life Technologies Corp

Inventors

• Woolf Tod
• Wiederholt Kristin

Classifications

• A61P37/02

  Immunomodulators · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P31/20

  for DNA viruses · CPC title

• A61P31/12

  Antivirals · CPC title